Cancer Research The Future of Cancer Research: Science and Patient Impact  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 44, 597-601, February 1, 1984]
© 1984 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Brunda, M. J.
Right arrow Articles by Rosenbaum, D.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Brunda, M. J.
Right arrow Articles by Rosenbaum, D.

Modulation of Murine Natural Killer Cell Activity in Vitro and in Vivo by Recombinant Human Interferons

Michael J. Brunda1 and Deborah Rosenbaum

Department of Experimental and Applied Biology, Hoffmann-La Roche Inc., Nutley, New Jersey 07110

The ability of two subtypes of recombinant human {alpha} interferons (IFN), rIFN-{alpha}A and rIFN-{alpha}D, and two intramolecular hybrids, rIFN-{alpha}A/D and rIFN-{alpha}D/A, to modulate murine natural killer (NK) cell activity in vitro and in vivo was examined. The cytotoxic activity of murine spleen cells was markedly augmented by rIFN-{alpha}A/D following in vitro incubation, while the other IFN had little or no effect. The augmentation observed was dose dependent and inhibited by monoclonal antibody to rIFN-{alpha}A/D. Mice treated by one of several routes with rIFN-{alpha}A/D had elevated levels of NK activity in their spleen, peritoneal cavity, and peripheral blood following one to three daily injections. Augmentation of cytotoxicity was dose dependent in vivo and was less efficient or absent following treatment with the other recombinant IFN. When treatment was extended to ten or 12 daily i.p. injections, marked differences in NK levels resulted, depending upon the location from which cells were obtained. Following prolonged administration of rIFN-{alpha}A/D, a significant decrease in NK activity was seen with peripheral blood lymphocytes, while peritoneal cells retained elevated levels of activity; in spleen, NK activity was less than in mice treated for 3 days with rIFN-{alpha}A/D but greater than in control mice. Treatment of mice in vivo with IFN can either increase or decrease NK levels dependent upon both the length of treatment and the site at which the NK activity is measured. The use of rIFN-{alpha}A/D with murine cells is an excellent model to study the regulation of NK activity by IFN.

1 To whom requests for reprints should be addressed.

Received 5/26/83. Accepted 11/ 4/83.




This article has been cited by other articles:


Home page
J. Immunol.Home page
N. Casares, L. Arribillaga, P. Sarobe, J. Dotor, A. Lopez-Diaz de Cerio, I. Melero, J. Prieto, F. Borras-Cuesta, and J. J. Lasarte
CD4+/CD25+ Regulatory Cells Inhibit Activation of Tumor-Primed CD4+ T Cells with IFN-{gamma}-Dependent Antiangiogenic Activity, as well as Long-Lasting Tumor Immunity Elicited by Peptide Vaccination
J. Immunol., December 1, 2003; 171(11): 5931 - 5939.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1984 by the American Association for Cancer Research.